InSite Vision to Report Third Quarter 2012 Financial Results on November 8,
ALAMEDA, Calif. -- October 26, 2012
InSite Vision Incorporated (OTCBB:INSV) announced today that it will report
financial results for the third quarter ended September 30, 2012 on Thursday,
November 8, 2012.
Company management will host a conference call that day beginning at 4:30 p.m.
ET/1:30 p.m. PT to discuss third quarter financial results and to review
recent accomplishments and upcoming milestones. Investors will be invited to
ask questions following management’s prepared remarks.
Analysts and investors can participate in the conference call by dialing
888-679-8037 for domestic callers and 617-213-4849 for international callers
using the pass code 68680828. A telephone replay will be available following
the conclusion of the call by dialing 888-286-8010 for domestic callers and
617-801-6888 for international callers using the pass code 27814489.
The live conference call will also be webcast and available on the Investor
Relations page of the company's website at www.insitevision.com. A press
release detailing third quarter 2012 financial results will be posted to the
company's website and furnished to the Securities and Exchange Commission on a
About InSite Vision
InSite Vision is advancing new ophthalmic products for unmet eye care needs
based on its innovative DuraSite^® and DuraSite 2^® platform technologies. The
DuraSite and DuraSite 2 drug delivery systems extend the duration of drug
retention on the surface of the eye, thereby reducing frequency of treatment
and improving the efficacy of topical drugs. DuraSite is currently leveraged
in two commercial products for the treatment of bacterial eye infections,
AzaSite^® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by
Merck, and Besivance^® (besifloxacin ophthalmic suspension) 0.6%, marketed by
Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic
therapeutics through Phase 3 clinical studies: AzaSite Plus^™ and DexaSite^™
for the treatment of eye infections, and BromSite^™ for pain and swelling
associated with ocular surgery. DuraSite 2 incorporates InSite’s proprietary
bioadhesive core technology with a cationic polymer to achieve sustained and
enhanced ocular delivery of drugs. The DuraSite 2 platform will be applied to
InSite’s future pipeline product candidates and available through a broad
licensing program for advanced ophthalmic drug development. For further
information on InSite Vision, please visit www.insitevision.com.
AzaSite^® and DuraSite^® are registered trademarks of InSite Vision
BESIVANCE^® is a registered trademark of Bausch + Lomb Incorporated.
Louis Drapeau, 510-747-1220
Chief Financial Officer
Media and Investor Inquiries
Michelle Corral, 415-794-8662
Karen L. Bergman, 650-575-1509
Press spacebar to pause and continue. Press esc to stop.